All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news


← First12345...798Next →

hiv & aids news selected from other sources

  • Hepatitis C
    New hepatitis data highlight need for urgent global response
    World Health Organization | 21 April 2017

    New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and death.

  • Access to medicines and treatment
    The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir
    Medicines Patent Pool | 21 April 2017

    The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low- and middle-income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.

  • Prevention of mother-to-child transmission
    The living legacy of the Global Plan: eliminating HIV in children
    UNAIDS | 20 April 2017

    The Journal of Acquired Immune Deficiency Syndromes (JAIDS) has released a special supplement on the incredible journey of the Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive (Global Plan), which documents the history of the Global Plan and outlines what the future holds as efforts to end AIDS among women, children and adolescents accelerate.

  • PrEP
    Anti-HIV drug removes personal responsibility
    Irish Times | 20 April 2017

    I would argue that Pre-exposure Prophylaxis is a solution which removes personal responsibility in relation to the transmission of HIV, increases the practice of unprotected sexual behaviour and will, ultimately, be responsible for widespread liver disease among gay populations in 10-15 years from now.

  • Hepatitis C symptoms and diagnosis
    Long-term antibiotic prophylaxis reduces mortality in people with advanced liver disease
    EASL press release | 20 April 2017

    A multicenter, randomized, controlled study presented today found that long-term oral antibiotic therapy with norfloxacin improved the prognosis of people with life-threatening advanced liver disease. The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that norfloxacin administration for six months was associated with a reduced risk of death and infection at six months in patients with Child-Pugh class C cirrhosis, a very severe and advanced stage of liver disease.

  • The search for a cure
    Defective HIV proviruses hinder immune system response and cure
    Science Daily | 19 April 2017

    HIV proviruses can outnumber functional HIV 1000 copies to one and the faulty proteins they create can complicate efforts to measure a patient's viral load, exhaust immune systems, shield functional HIV from attack by natural means or drugs, and seriously complicate the development of a cure.

  • Global health initiatives
    The Future Of Investment In PEPFAR: Understanding PEPFAR’s Multiple Economic, Health, And Diplomatic Impacts
    Health Affairs | 19 April 2017

    At a time when the future of the program is in doubt due to possibly severe budget cuts to the US State Department (where PEPFAR is based) proposed by the new administration, we thought it would be an opportune moment to highlight some of the key studies we have published exploring PEPFAR’s role in fighting the HIV/AIDS epidemic.

  • PrEP
    Open letter to Gilead Sciences about PrEP by EATG and the PrEP in Europe Initiative
    EATG / PrEP in Europe | 18 April 2017

    Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).

  • Pharmaceutical industry
    Top 10 Pharmaceutical Companies 2017
    LinkedIn | 18 April 2017

    The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

  • Pharmaceutical industry
    Destroy Them: One Way to Up Price of Generic Cancer Drugs
    Medscape | 18 April 2017

    In a now-leaked email, a senior executive at a large pharmaceutical company discussed destroying supplies of generic cancer drugs as part of a pricing battle with health authorities in Spain, according to a report in the British newspaper The Times.

← First12345...1303Next →

Conference news

News from the Conference on Retroviruses and Opportunistic Infections (CROI 2017).

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Achieving the 90-90-90 target

With advances in HIV testing, treatment and care, some countries are making great progress towards the UNAIDS 90-90-90 target.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.